Stack Name
GLOW Stack
Updated February 2026
GLOW Stack Protocol - BPC-157 + TB-500 + GHK-Cu
Three-peptide protocol reference extending Wolverine with GHK-Cu-driven collagen remodeling and tissue-quality control.
Compounds
BPC-157 + TB-500 + GHK-Cu
Cycle
4-8 weeks typical
Blend Ratio
5:1:1 (GHK-Cu dominant)
Status
Not FDA-approved
COA-Verified Suppliers Carrying GLOW Stack Products
Research-grade peptide suppliers vetted for COAs, purity data, and reliability.Affiliate disclosure: some outbound supplier links are affiliate links, and we may earn a commission at no extra cost to you. This supports our free tools and protocol database.
Discount code: PEPPAL
Quick Reference Card
Aliases
GLOW Blend; GLOW Peptide; BPC-157 + TB-500 + GHK-Cu Stack; Triple Repair Stack
Category
Combined Tissue Repair + Skin Rejuvenation Stack
BPC-157
250-500 mcg daily
TB-500
2-5 mg 2x/week
GHK-Cu
1-2 mg daily
Common Blend
5:1:1 (GHK-Cu : TB-500 : BPC-157)
Cycle Length
4-8 weeks (extended up to 12)
Regulatory
No injectable compound is FDA-approved; BPC-157 and TB-500 are WADA-prohibited.
What Is the GLOW Stack?
The GLOW Stack combines BPC-157, TB-500, and GHK-Cu as a three-peptide model for tissue repair plus skin-quality remodeling. It extends Wolverine by adding a collagen/ECM and gene-modulation layer.
BPC-157 contributes vascular and cytoprotective support, TB-500 contributes migration and systemic repair organization, and GHK-Cu contributes collagen/elastin remodeling plus broad gene-expression effects.
No clinical trial has evaluated this three-peptide combination. Current use is based on individual-compound data and community protocol patterns.
Why Add GHK-Cu to Wolverine?
Foundation: Wolverine (BPC-157 + TB-500)
Wolverine covers vascular support and cellular migration. GLOW adds a tissue-quality layer rather than replacing those pathways.
Quality Layer: GHK-Cu
GHK-Cu adds copper-dependent collagen/elastin support, ECM remodeling, and broad gene-expression regulation. This shifts the model from repair-only to repair-plus-remodeling.
Anti-Inflammatory Convergence
All three compounds contribute anti-inflammatory effects through different pathways, creating a multi-layer inflammatory-environment strategy.
Anti-Fibrotic Convergence
TB-500 and GHK-Cu together support more organized remodeling by balancing connective tissue synthesis and turnover.
GLOW Stack Dosing Protocol & Schedule
Evidence Level Notice
No clinical trial has evaluated BPC-157 + TB-500 + GHK-Cu together. Protocol structure is community-derived.
Protocol Format Options
Separate Vials
Best for injury-focused workflows where BPC-157, TB-500, and GHK-Cu doses need independent control.
Standard GLOW Protocol (Separate Vials)
Compound: BPC-157
Loading (Weeks 1-4): 250-500 mcg/day
Maintenance (Weeks 5-8+): 250 mcg/day
Frequency: Daily
Route: SubQ near injury or oral
Compound: TB-500
Loading (Weeks 1-4): 2.5-5 mg per injection
Maintenance (Weeks 5-8+): 2 mg per injection
Frequency: 2x/week
Route: SubQ systemic
Compound: GHK-Cu
Loading (Weeks 1-4): 1-2 mg/day
Maintenance (Weeks 5-8+): 1 mg/day
Frequency: Daily
Route: SubQ
Weekly Schedule Example
Day: Monday
BPC-157: 500 mcg
TB-500: 2.5 mg
GHK-Cu: 1-2 mg
Day: Tuesday
BPC-157: 500 mcg
TB-500: -
GHK-Cu: 1-2 mg
Day: Wednesday
BPC-157: 500 mcg
TB-500: -
GHK-Cu: 1-2 mg
Day: Thursday
BPC-157: 500 mcg
TB-500: 2.5 mg
GHK-Cu: 1-2 mg
Day: Friday
BPC-157: 500 mcg
TB-500: -
GHK-Cu: 1-2 mg
Day: Saturday
BPC-157: 500 mcg
TB-500: -
GHK-Cu: 1-2 mg
Day: Sunday
BPC-157: 500 mcg
TB-500: -
GHK-Cu: 1-2 mg
Pre-Blended GLOW Vial
Convenience-first format using the common 5:1:1 ratio (GHK-Cu dominant).
Blend Setup Reference
Parameter: Blend composition
Typical Value: 70 mg total (50 mg GHK-Cu + 10 mg TB-500 + 10 mg BPC-157)
Parameter: Common reconstitution
Typical Value: 3 mL bacteriostatic water
Parameter: Total concentration
Typical Value: 23.3 mg/mL total blend
Parameter: Common daily dose
Typical Value: 0.10 mL (10 units) = ~2.33 mg total blend
Parameter: Typical cycle
Typical Value: 4-6 weeks (extend to 8-12 in select workflows)
Per-Injection Delivery From 5:1:1 Blend
Daily Units: 10 units
Total Blend: ~2.33 mg
GHK-Cu: ~1.67 mg
TB-500: ~0.33 mg
BPC-157: ~0.33 mg
Pre-Blend Dose Assessment
Component: GHK-Cu
Per-dose from Blend: ~1.67 mg
Typical Standalone: 1-2 mg daily
Assessment: In range
Component: BPC-157
Per-dose from Blend: ~0.33 mg
Typical Standalone: 0.25-0.5 mg daily
Assessment: In range
Component: TB-500
Per-dose from Blend: ~0.33 mg
Typical Standalone: 2-5 mg per injection, 2x/week
Assessment: Often below standalone injury range
The 5:1:1 blend is optimized for convenience and skin/remodeling goals more than TB-500-heavy injury protocols.
Cycle Guidelines
Approach: Standard
Duration: 4-6 weeks
Off Period: 2-4 weeks
Best For: Skin + general healing
Approach: Extended
Duration: 8-12 weeks
Off Period: 4-8 weeks
Best For: Complex recovery
Approach: Skin-focused blend
Duration: 4 weeks
Off Period: 2-4 weeks
Best For: Anti-aging priority
- On TB-500 days, all three can be administered in one session using separate syringes.
- Separate-vial workflows preserve injury-site targeting for BPC-157 while keeping TB-500/GHK-Cu systemic.
- Pre-blended workflows reduce injection burden to one daily injection but limit independent dose control.
Protocol Notes
Separate-vial logistics can require up to three injections daily (BPC-157 + GHK-Cu daily, plus TB-500 on 2x/week days). Use separate syringes and do not mix separate-vial compounds in one syringe due to stability/pH differences. Pre-blended vials simplify this to one daily injection but limit dose flexibility. GHK-Cu cycling (30-60 days on, equal off) typically governs total GLOW cycle planning. Some users keep topical GHK-Cu during injectable off-cycles.
GLOW Stack Reconstitution Guide
Reconstitution Format Options
Separate Vials
Independent reconstitution of BPC-157, TB-500, and GHK-Cu allows maximum dosing flexibility.
BPC-157 Reconstitution
Vial: 5 mg
BAC Water: 2 mL
Concentration: 2,500 mcg/mL
250 mcg: 10 units
500 mcg: 20 units
Vial: 10 mg
BAC Water: 2 mL
Concentration: 5,000 mcg/mL
250 mcg: 5 units
500 mcg: 10 units
TB-500 Reconstitution
Vial: 5 mg
BAC Water: 1 mL
Concentration: 5 mg/mL
2.5 mg: 50 units
5 mg: 100 units
Vial: 10 mg
BAC Water: 2 mL
Concentration: 5 mg/mL
2.5 mg: 50 units
5 mg: 100 units
GHK-Cu Reconstitution
Vial: 50 mg
BAC Water: 5 mL
Concentration: 10 mg/mL
1 mg: 10 units
2 mg: 20 units
Vial: 100 mg
BAC Water: 10 mL
Concentration: 10 mg/mL
1 mg: 10 units
2 mg: 20 units
Math verification (separate vials): BPC-157: 5,000 mcg ÷ 2 mL = 2,500 mcg/mL -> 500 mcg = 0.20 mL = 20 units. TB-500: 5 mg ÷ 1 mL = 5 mg/mL -> 2.5 mg = 0.50 mL = 50 units. GHK-Cu: 50 mg ÷ 5 mL = 10 mg/mL -> 1 mg = 0.10 mL = 10 units.
Pre-Blended GLOW Vial
The standard 70 mg 5:1:1 blend is reconstituted once and dosed as a single daily shot.
Blend Reconstitution Math (70 mg Total)
Metric: Blend composition
Value: 50 mg GHK-Cu + 10 mg TB-500 + 10 mg BPC-157
Metric: BAC water added
Value: 3 mL
Metric: Total concentration
Value: 23.3 mg/mL total blend
Metric: Standard daily dose
Value: 0.10 mL (10 units) = ~2.33 mg total
Component Delivery at 10 Units
GHK-Cu: ~1.67 mg
TB-500: ~0.33 mg
BPC-157: ~0.33 mg
- BPC-157 is dosed in micrograms; TB-500 and GHK-Cu are dosed in milligrams.
- Do not confuse mcg and mg dosing units across compounds; label every vial clearly.
- TB-500 is the shortest reconstituted stability window (1-2 weeks).
- GHK-Cu may show a slight blue/green tint after reconstitution.
Standard 7-Step Reconstitution (All Three)
- Wipe stopper with alcohol and allow to dry.
- Draw BAC water volume into sterile syringe.
- Direct water against vial wall, not onto powder.
- Allow gentle flow down the glass.
- Roll 30-60 seconds; do not shake.
- Inspect for expected clarity/color.
- Label and refrigerate at 2-8C.
Calculator
Use the Peptide Reconstitution Calculator for three-vial GLOW math.
GLOW Stack Side Effects & Safety
Individual profiles are generally favorable in available research, but no clinical trial has tested the triple combination directly.
Key consideration areas are amplified angiogenic signaling, added copper exposure from GHK-Cu (cycling required), and increased contamination exposure from multi-peptide sourcing.
- Common reports: injection-site irritation, short-term fatigue during TB-500 loading, occasional headache.
- GHK-Cu-specific: cycling and copper-handling context should be respected.
- Practical risk remains supplier and batch quality.
Clinical Evidence Context
Critical Note
No published studies evaluate BPC-157 + TB-500 + GHK-Cu as a combined stack.
Evidence exists for each component individually. BPC-157 has large preclinical coverage, TB-500 has human safety and Phase II signals, and GHK-Cu has topical and mechanistic data including collagen-density and gene-modulation findings.
The triple rationale is pathway complementarity: vascular support (BPC-157), cellular migration support (TB-500), and tissue-quality remodeling (GHK-Cu).
Storage & Handling
: Lyophilized
BPC-157: -20C long-term
TB-500: -20C long-term
GHK-Cu: -20C long-term
: Reconstituted
BPC-157: 2-8C, up to 30 days
TB-500: 2-8C, 1-2 weeks
GHK-Cu: 2-8C, up to 30 days
: Appearance
BPC-157: Clear
TB-500: Clear
GHK-Cu: May be light blue/green
: Freeze reconstituted
BPC-157: Aliquots possible
TB-500: Do not freeze
GHK-Cu: Do not freeze
TB-500 remains the limiting reconstitution window in most separate-vial workflows.
GLOW vs Wolverine vs Individual Peptides
Feature: Mechanisms
GLOW: Repair + migration + collagen remodeling
Wolverine: Repair + migration
BPC-157: Local repair
TB-500: Systemic migration
GHK-Cu: Collagen/ECM quality
Feature: Skin/Anti-Aging
GLOW: Excellent
Wolverine: Moderate
BPC-157: Low
TB-500: Low
GHK-Cu: Excellent
Feature: Injury Repair
GLOW: Excellent
Wolverine: Excellent
BPC-157: Good
TB-500: Good
GHK-Cu: Moderate
Feature: Complexity
GLOW: High
Wolverine: Moderate
BPC-157: Low
TB-500: Low
GHK-Cu: Low
Feature: Cost
GLOW: Highest
Wolverine: Moderate
BPC-157: Lower
TB-500: Lower
GHK-Cu: Lower
Internal Linking Map
Link: Homepage (breadcrumb)
From Section: Schema / Header
To: https://www.peptidedosingprotocols.com
Link: PepPal Calculator
From Section: Reconstitution + FAQ
To: https://www.peppal.app/calculator
Link: Wolverine Stack
From Section: Mechanism + Comparison + Related
To: /stacks/wolverine-stack
Link: BPC-157 Protocol
From Section: Quick context + Evidence + Related
To: /protocol/bpc-157
Link: TB-500 Protocol
From Section: Quick context + Evidence + Related
To: /protocol/tb-500
Link: GHK-Cu Protocol
From Section: Quick context + Evidence + Related
To: /protocol/ghk-cu
Link: KPV Protocol
From Section: Related stacks + Related protocols
To: /protocol/kpv
Link: Ipamorelin Protocol
From Section: Related stacks + Related protocols
To: /protocol/ipamorelin
Link: Orbitrex Peptides
From Section: Supplier section
To: https://www.orbitrexpeptides.com?ref=peppal
Link: Pivot Labs
From Section: Supplier section
To: https://www.pivot-labs.co/?ref=PEPPAL
Link: Peptide Tech
From Section: Supplier section
To: https://www.peptidetech.co/?ref=peppal
Frequently Asked Questions - GLOW Stack
Q1: What is the GLOW Stack?
It combines BPC-157, TB-500, and GHK-Cu to pair tissue-repair pathways with collagen and matrix-quality remodeling.
Q2: How do you dose the GLOW Stack?
Typical separate-vial dosing is BPC-157 daily, TB-500 twice weekly, and GHK-Cu daily, with cycle length often governed by GHK-Cu cycling.
Q3: What is the 5:1:1 ratio in the GLOW blend?
It is the common pre-blend weight ratio of GHK-Cu : TB-500 : BPC-157, which makes the blend GHK-Cu dominant.
Q4: How does the GLOW Stack differ from the Wolverine Stack?
GLOW adds GHK-Cu to Wolverine, introducing a dedicated tissue-quality and collagen-remodeling layer.
Q5: How do you reconstitute three separate peptides for the GLOW Stack?
Each peptide is reconstituted separately with BAC water directed against the vial wall. Unit handling matters most: BPC-157 is dosed in mcg, while TB-500 and GHK-Cu are dosed in mg. Label each vial and account for TB-500's shorter 1-2 week stability window.
Q6: What results can be expected from the GLOW Stack?
Community reporting generally places early inflammation/pain improvements in 1-2 weeks, visible skin quality improvements in 2-4 weeks, and deeper remodeling over 4-8+ weeks.
Q7: Is the GLOW Stack safe?
Individual peptide safety profiles are generally favorable, but no trial has evaluated the triple combination. Key considerations are combined angiogenic signaling, copper cycling requirements from GHK-Cu, and supplier quality controls.
Q8: How long should you run the GLOW Stack?
Common planning is 4-6 weeks on with 2-4 weeks off, with extended options in selected cases. GHK-Cu cycling requirements usually set the overall cycle length.
Q9: Should you use a pre-blended GLOW vial or separate vials?
Separate vials provide dose flexibility and are usually preferred for injury-focused workflows; pre-blends prioritize convenience and skin-focused use cases.
Q10: Can you inject all three peptides at the same time?
Yes. All three can be used in the same session, but separate syringes are preferred for separate-vial workflows.
Q11: Does the GLOW Stack help with skin anti-aging?
Yes. This is a primary reason people use GLOW, mainly due to the GHK-Cu component and its collagen/remodeling role.
Q12: Can you add KPV to the GLOW Stack?
Yes. The four-peptide extension is often called KLOW for inflammation-heavy contexts.
Q13: What calculator should I use?
Use the PepPal calculator: https://www.peppal.app/calculator
Q14: Is this medical advice?
No. This is an educational research reference.
Sources & Research
- Vasireddi N, et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." Orthopaedic Journal of Sports Medicine, 2025.
- Ruff D, et al. "A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers." Annals of the New York Academy of Sciences, 2010.
- Pickart L, Margolina A "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, 2018 Link.
- Bock-Marquette I, et al. "Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature, 2004.
- Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature, 2007.
- Pickart L, et al. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International, 2015 Link.
- Yuvan Research / McGill University "Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial." EurekAlert, 2024.
- Ehrlich HP, Hazard SW "Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts." Annals of the New York Academy of Sciences, 2010.
- Gwyer D, et al. "Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell and Tissue Research, 2019.
- Philp D, et al. "Thymosin beta4 promotes angiogenesis, wound healing, and hair growth." FASEB Journal, 2004.
- Sikiric P, et al. "The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity." Pharmaceuticals, 2024 Link.
- Broad Institute Connectivity Map "Gene expression analysis of GHK-Cu." CLUE, 2024 Link.
Related Protocols
Stack Protocol
Wolverine Stack
Two-peptide tissue repair model
View protocolHalf-life: <30 min
BPC-157
Tissue Repair / Cytoprotective
View protocolHalf-life: <2 hours
TB-500
Tissue Repair / Actin Sequestration
View protocolHalf-life: ~30-60 min
GHK-Cu
Collagen Remodeling / Anti-Aging
View protocolPeptide Fragment
KPV
Anti-Inflammatory
View protocolHalf-life: ~2 hours
Ipamorelin
GH Secretagogue
View protocolDisclaimer
BPC-157, TB-500, and GHK-Cu are not FDA-approved for injection. No clinical trials have evaluated the three-peptide combination.
Affiliate disclosure: some outbound supplier links are affiliate links, and we may earn a commission at no extra cost to you. This supports our free tools and protocol database. The information on this page is for educational and research reference purposes only. No compounds discussed on this site are intended for human consumption. This is not medical advice. Consult a qualified healthcare professional before considering any peptide protocol.